Literature DB >> 17076973

A randomized, controlled, open-label trial of a single day of mebendazole versus a single dose of tinidazole in the treatment of giardiasis in children.

Roberto Cañete1, Angel A Escobedo, Maria Elena González, Pedro Almirall, Nereyda Cantelar.   

Abstract

BACKGROUND: Giardia duodenalis is the most commonly detected parasite in the intestinal tract of humans and 5-nitroimidazole compounds, quinacrine and furazolidone have been used against giardiasis. However, cases refractory to treatment with these drugs are becoming more common worldwide.
OBJECTIVE: To compare the efficacy and safety of mebendazole versus tinidazole in the treatment of giardiasis. RESEARCH DESIGN AND METHODS: 122 children (aged 5 to 15 years) of both sexes with confirmed Giardia duodenalis cysts or trophozoites in their stool samples were randomly separated into two groups of 61 individuals. Each group received either mebendazole 200 mg three times for 1 day or tinidazole 50 mg/kg in a single dose. The evaluation of the efficacy was based on parasitological response. Parents or legal guardians of each child were asked to provide three fecal samples on days 3, 5, and 7 after treatment completion. A child was considered to be cured if no Giardia trophozoites or cysts were found in any of the three post-treatment fecal specimens evaluated by direct wet mounts and/or after Ritchie concentration techniques.
RESULTS: The frequency of cure was higher for tinidazole (81.97%) than for mebendazole (63.93%); the difference was statistically significant (p < 0.05). Transient abdominal pain was more common in children treated with mebendazole (p < 0.05), whereas loss of appetite, bitter taste, headache, vomiting, and nausea were more common in the tinidazole-treated group (p < 0.05).
CONCLUSIONS: Three doses of mebendazole, in a single day, are inferior to a single dose tinidazole in the treatment of giardiasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17076973     DOI: 10.1185/030079906X132497

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  13 in total

1.  Discovery of novel antigiardiasis drug candidates.

Authors:  Liudmila Kulakova; Andrey Galkin; Catherine Z Chen; Noel Southall; Juan J Marugan; Wei Zheng; Osnat Herzberg
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

2.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

Review 3.  Understanding drug resistance in human intestinal protozoa.

Authors:  Hend Aly El-Taweel
Journal:  Parasitol Res       Date:  2015-03-19       Impact factor: 2.289

4.  Structural basis for inactivation of Giardia lamblia carbamate kinase by disulfiram.

Authors:  Andrey Galkin; Liudmila Kulakova; Kap Lim; Catherine Z Chen; Wei Zheng; Illarion V Turko; Osnat Herzberg
Journal:  J Biol Chem       Date:  2014-02-20       Impact factor: 5.157

5.  Treatment of giardiasis in common marmosets (Callithrix jacchus) with tinidazole.

Authors:  Joshua A Kramer; Audra M Hachey; Lynn M Wachtman; Keith G Mansfield
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

6.  Giardial triosephosphate isomerase as possible target of the cytotoxic effect of omeprazole in Giardia lamblia.

Authors:  Horacio Reyes-Vivas; Ignacio de la Mora-de la Mora; Adriana Castillo-Villanueva; Lilian Yépez-Mulia; Gloria Hernández-Alcántara; Rosalia Figueroa-Salazar; Itzhel García-Torres; Saúl Gómez-Manzo; Sara T Méndez; América Vanoye-Carlo; Jaime Marcial-Quino; Angélica Torres-Arroyo; Jesús Oria-Hernández; Pedro Gutiérrez-Castrellón; Sergio Enríquez-Flores; Gabriel López-Velázquez
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

7.  Mebendazole compared with secnidazole in the treatment of adult giardiasis: a randomised, no-inferiority, open clinical trial.

Authors:  Pedro Almirall; Angel A Escobedo; Idalia Ayala; Maydel Alfonso; Yohana Salazar; Roberto Cañete; Sergio Cimerman; Martha Galloso; Ilmaems Olivero; Maytee Robaina; Karen Tornés
Journal:  J Parasitol Res       Date:  2011-11-20

Review 8.  Efficacy of 5-nitroimidazoles for the treatment of giardiasis: a systematic review of randomized controlled trials.

Authors:  Vinay Pasupuleti; Angel Arturo Escobedo; Abhishek Deshpande; Priyaleela Thota; Yuani Roman; Adrian V Hernandez
Journal:  PLoS Negl Trop Dis       Date:  2014-03-13

9.  Mebendazole Is a Potential Alternative in the Treatment of Giardia duodenalis Infection.

Authors:  Roberto Cañete
Journal:  Curr Ther Res Clin Exp       Date:  2016-05-31

10.  The old and new therapeutic approaches to the treatment of giardiasis: where are we?

Authors:  Haendel G N O Busatti; Joseph F G Santos; Maria A Gomes
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.